{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:07:08Z","timestamp":1761664028633,"version":"build-2065373602"},"reference-count":102,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.repc.2019.05.008","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T08:15:37Z","timestamp":1581581737000},"page":"883-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A evolu\u00e7\u00e3o hist\u00f3rica do envolvimento dos sistemas neuro\u2010humorais no conhecimento da fisiopatologia e do tratamento da insufici\u00eancia card\u00edaca"],"prefix":"10.1016","volume":"38","author":[{"given":"Jorge","family":"Pol\u00f3nia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Rocha","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2019.05.008_bib0515","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.05.008_bib0520","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"34820348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2019.05.008_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Hear Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0530","doi-asserted-by":"crossref","first-page":"H1928","DOI":"10.1152\/ajpheart.2001.280.5.H1928","article-title":"Cardiac excitation\u2010contraction coupling: role of membrane potential in regulation of contraction","volume":"280","author":"Ferrier","year":"2001","journal-title":"Hear Circ Physiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0535","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yjmcc.2015.10.029","article-title":"Monocyte and macrophage subsets along the continuum to heart failure: Misguided heroes or targetable villains?","volume":"89","author":"Glezeva","year":"2015","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0540","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10741-012-9365-4","article-title":"Fibrosis and heart failure","volume":"19","author":"Segura","year":"2014","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0545","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10741-013-9405-8","article-title":"Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target","volume":"19","author":"Glezeva","year":"2014","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0550","first-page":"129","article-title":"Mecanismos neuro\u2010hormonais na insufici\u00eancia card\u00edaca \u2010 da fisiopatologia ao tratamento","volume":"8","author":"Cerqueira-Gomes","year":"1989","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0555","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/jcm5070062","article-title":"Heart Failure: Diagnosis. management and utilization","volume":"5","author":"Inamdar","year":"2016","journal-title":"J Clin Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0560","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1745-0179-1-19","article-title":"Heart failure and health related quality of life","volume":"1","author":"Coelho","year":"2005","journal-title":"Clin Pract Epidemiol Ment Health."},{"key":"10.1016\/j.repc.2019.05.008_bib0565","first-page":"30","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Publ Gr."},{"key":"10.1016\/j.repc.2019.05.008_bib0570","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ijcard.2012.11.065","article-title":"Worldwide risk factors for heart failure: a systematic review and pooled analysis","volume":"168","author":"Khatibzadeh","year":"2013","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0575","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"Van Riet","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0580","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"Ceia","year":"2002","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0585","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.repc.2017.11.010","article-title":"Heart failure in numbers: Estimates for the 21st century in Portugal","volume":"37","author":"Fonseca","year":"2018","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0590","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.repc.2016.11.013","article-title":"Sacubitril\/valsartan: um importante avan\u00e7o no puzzle terap\u00eautico da insufici\u00eancia card\u00edaca","volume":"36","author":"Marques da Silva","year":"2017","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0595","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-8703(81)90739-0","article-title":"Neurohumoral control mechanisms in congestive heart failure","volume":"102","author":"Cohn","year":"1981","journal-title":"Am Heart J."},{"key":"10.1016\/j.repc.2019.05.008_bib0600","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/ki.1987.156","article-title":"Renal and circulatory mechanisms in congestive heart failure","volume":"31","author":"Dzau","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/j.repc.2019.05.008_bib0605","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0610","doi-asserted-by":"crossref","unstructured":"Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201035.","DOI":"10.1056\/NEJM198706043162301"},{"key":"10.1016\/j.repc.2019.05.008_bib0615","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0620","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.repc.2019.05.008_bib0625","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0630","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamainternmed.2014.3258","article-title":"A. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure","volume":"174","author":"Pasternak","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.repc.2019.05.008_bib0635","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo\u2010controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2019.05.008_bib0640","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0002-9343(65)90211-1","article-title":"Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure","volume":"39","author":"Chidsey","year":"1965","journal-title":"Am J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0645","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9149(78)90162-5","article-title":"Plasma norepinephrine in congestive heart failure","volume":"41","author":"Thomas","year":"1978","journal-title":"Am J Cardiol."},{"issue":"2B","key":"10.1016\/j.repc.2019.05.008_bib0650","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0002-9343(86)90148-8","article-title":"Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure","volume":"80","author":"Ruffolo","year":"1986","journal-title":"Am J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0655","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/0167-5273(84)90179-7","article-title":"Myocardial beta\u2010adrenergic receptor downregulation in heart failure","volume":"5","author":"Bristow","year":"1984","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0660","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccl.2013.09.010","article-title":"The sympathetic nervous system and heart failure","volume":"32","author":"Zhang","year":"2014","journal-title":"Cardiol Clin."},{"key":"10.1016\/j.repc.2019.05.008_bib0665","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","article-title":"The autonomic nervous system and heart failure","volume":"114","author":"Florea","year":"2014","journal-title":"Circ Res."},{"key":"10.1016\/j.repc.2019.05.008_bib0670","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10741-012-9368-1","article-title":"Angiotensin II, sympathetic nerve activity and chronic heart failure","volume":"19","author":"Wang","year":"2014","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0675","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/eurheartj\/ehv087","article-title":"The sympathetic\/parasympathetic imbalance in heart failure with reduced ejection fraction","volume":"36","author":"Floras","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.05.008_bib0680","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/01.HYP.1.4.384","article-title":"Tigerstedt and the discovery of renin. An historical note","volume":"1","author":"Marks","year":"1979","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2019.05.008_bib0685","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1113\/jphysiol.1940.sp003850","article-title":"The substance causing renal hypertension","volume":"98","author":"Braun-Mendendez","year":"1940","journal-title":"J Physiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.71.1.29","article-title":"A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin\u2010activator","volume":"71","author":"Page","year":"1940","journal-title":"J Exp Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0695","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(87)90178-0","article-title":"Implications of local angiotensin production in cardiovascular physiology and pharmacology","volume":"59","author":"Dzau","year":"1987","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0700","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/postgradmedj-2016-134045","article-title":"The renin\u2010angiotensin\u2010aldosterone system in heart failure for the non\u2010specialist: the past, the present and the future","volume":"93","author":"Orsborne","year":"2017","journal-title":"Postgrad Med J."},{"key":"10.1016\/j.repc.2019.05.008_bib0705","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","article-title":"The renin\u2010angiotensin\u2010aldosterone system and heart failure","volume":"32","author":"Sayer","year":"2014","journal-title":"Cardiol Clin."},{"key":"10.1016\/j.repc.2019.05.008_bib0710","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2015.01.033","article-title":"The path to an angiotensin receptor antagonist\u2010neprilysin inhibitor in the treatment of heart failure","volume":"65","author":"Braunwald","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0715","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.102.3.351","article-title":"Improvement of endothelial function by chronic angiotensin\u2010converting enzyme inhibition in heart failure?: role of nitric oxide, prostanoids, oxidant stress, and bradykinin","volume":"102","author":"Varin","year":"2000","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib0720","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0725","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0730","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0735","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin\u2010angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0740","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/00005344-198600087-00019","article-title":"Role of vasopressin in experimental congestive cardiac failure","volume":"8","author":"Johnston","year":"1986","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.repc.2019.05.008_bib0745","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cellsig.2015.07.021","article-title":"Arginine vasopressin receptor signaling and functional outcomes in heart failure","volume":"28","author":"Wasilewski","year":"2016","journal-title":"Cell Signal."},{"issue":"SUPPL. 1","key":"10.1016\/j.repc.2019.05.008_bib0750","first-page":"7","article-title":"Hyponatremia in heart failure: The role of arginine vasopressin and its antagonism","volume":"16","author":"Rosner","year":"2010","journal-title":"Congest Hear Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0755","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4330\/wjc.v6.i12.1252","article-title":"Arginine vasopressin as a target in the treatment of acute heart failure","volume":"6","author":"Gilotra","year":"2014","journal-title":"World J Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0760","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature."},{"key":"10.1016\/j.repc.2019.05.008_bib0765","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/00004872-199816080-00001","article-title":"Endothelin as a regulator of cardiovascular function in health and disease","volume":"16","author":"Haynes","year":"1998","journal-title":"J Hypertens."},{"key":"10.1016\/j.repc.2019.05.008_bib0770","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/107424840200700i102","article-title":"Endothelin in health and disease: Endothelin receptor antagonists in the management of pulmonary artery hypertension","volume":"7","author":"Kim","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"10.1016\/j.repc.2019.05.008_bib0775","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s001090050363","article-title":"Endothelin antagonism with bosentan: a review of potential applications","volume":"77","author":"Roux","year":"1999","journal-title":"J Mol Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0780","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2169\/internalmedicine.33.579","article-title":"Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis","volume":"33","author":"Yamane","year":"1994","journal-title":"Intern Med."},{"key":"10.1016\/j.repc.2019.05.008_bib1025","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib0790","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM198402093100603","article-title":"Prostaglandins in severe congestive heart failure","volume":"310","author":"Dzau","year":"1984","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1987.164","article-title":"The clinical significance of inhibition of renal prostaglandin synthesis","volume":"32","author":"Patrono","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/j.repc.2019.05.008_bib0800","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1986.84","article-title":"Prostaglandins and the control of the circulation","volume":"39","author":"Nies","year":"1986","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.repc.2019.05.008_bib0805","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.CIR.74.6.1203","article-title":"Evidence for a direct renal stimulating effect of prostaglandin E2 on renin release in patients with congestive heart failure","volume":"74","author":"Olivari","year":"1986","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib0810","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02125831","article-title":"The role of prostaglandins in mediating the effects of angiotensin converting enzyme inhibitors and other antihypertensive drugs","volume":"1","author":"Swartz","year":"1987","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.repc.2019.05.008_bib0815","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.hfc.2008.03.002","article-title":"Renal consequences of prostaglandin inhibition in heart failure","volume":"4","author":"Akinbamowo","year":"2008","journal-title":"Heart Fail Clin."},{"key":"10.1016\/j.repc.2019.05.008_bib0820","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.1995.262","article-title":"Nitric oxide and the glomerulus","volume":"48","author":"Raij","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.repc.2019.05.008_bib0825","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0002-9343(85)90338-9","article-title":"Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities","volume":"78","author":"Viquerat","year":"1985","journal-title":"Am J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0830","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0002-9149(83)90526-X","article-title":"Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy","volume":"52","author":"Pierpont","year":"1983","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0835","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/156720211796558032","article-title":"Dopamine and vascular dynamics control: Present status and future perspectives","volume":"8","author":"Tayebati","year":"2011","journal-title":"Curr Neurovasc Res."},{"key":"10.1016\/j.repc.2019.05.008_bib0840","first-page":"2014","article-title":"Atrial natriuretic peptide and renal dopaminergic system: A positive friendly relationship?","author":"Choi","year":"2014","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.repc.2019.05.008_bib0845","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/01.CIR.72.2.245","article-title":"Dopamine receptors: Applications in clinical cardiology","volume":"72","author":"Goldberg","year":"1985","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib0850","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/26.12.83339","article-title":"Atrial specific granules of the rat heart: light microscopic staining and histochemical reactions","volume":"26","author":"de Bold","year":"1978","journal-title":"J Histochem Cytochem."},{"key":"10.1016\/j.repc.2019.05.008_bib0855","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci"},{"key":"10.1016\/j.repc.2019.05.008_bib0860","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.2935937","article-title":"Atrial natriuretic peptide elevation in congestive heart failure in the human","volume":"231","author":"Burnett","year":"1986","journal-title":"Science (80\u2010)."},{"key":"10.1016\/j.repc.2019.05.008_bib0865","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature."},{"key":"10.1016\/j.repc.2019.05.008_bib0870","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI115146","article-title":"Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide","volume":"87","author":"Mukoyama","year":"1991","journal-title":"J Clin Invest."},{"key":"10.1016\/j.repc.2019.05.008_bib0875","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C\u2010Type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.repc.2019.05.008_bib0880","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000006997","article-title":"Evaluation of brain natriuretic peptide in the diagnosis of heart failure","volume":"93","author":"Bettencourt","year":"2000","journal-title":"Cardiology."},{"key":"10.1016\/j.repc.2019.05.008_bib0885","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/clc.4960231213","article-title":"Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction","volume":"23","author":"Bettencourt","year":"2000","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0890","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs1000557","article-title":"Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy","volume":"100","author":"Ferreira","year":"2001","journal-title":"Clin Sci (Lond)."},{"key":"10.1016\/j.repc.2019.05.008_bib0895","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10641969309032941","article-title":"Atrial natriuretic factor and changes in the aldosterone response to angiotensin II in sodium depleted dogs","volume":"15","author":"Richards","year":"1993","journal-title":"Clin Exp Hypertens."},{"key":"10.1016\/j.repc.2019.05.008_bib0900","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9343(88)90214-8","article-title":"Atrial natriuretic peptides and renin release","volume":"84","author":"Richards","year":"1988","journal-title":"Am J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0905","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.HYP.10.6.570","article-title":"Correlates of plasma atrial natriuretic factor in health and hypertension","volume":"10","author":"Montorsi","year":"1987","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2019.05.008_bib0910","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: Implications for therapy","volume":"19","author":"D\u00edez","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0915","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci."},{"key":"10.1016\/j.repc.2019.05.008_bib0920","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10741-014-9442-y","article-title":"BNP and NT\u2010proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review","volume":"19","author":"Santaguida","year":"2014","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0925","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2012.196","article-title":"Targeting the renin\u2010angiotensin\u2010aldosterone system in heart failure","volume":"10","author":"Lang","year":"2013","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.repc.2019.05.008_bib0930","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1574884708666131117125508","article-title":"A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF)","volume":"11","author":"Reed","year":"2015","journal-title":"Curr Cardiol Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0935","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev."},{"key":"10.1016\/j.repc.2019.05.008_bib0945","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-5793(93)80476-B","article-title":"Increased production of endothelin\u20101 in the hypertrophied rat heart due to pressure overload","volume":"332","author":"Yorikane","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.repc.2019.05.008_bib0950","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long\u2010term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: Primary results of the ENABLE Trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.repc.2019.05.008_bib0955","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.05.008_bib0960","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/gt.2011.18","article-title":"Plasmid\u2010based transient human stromal cell\u2010derived factor\u20101 gene transfer improves cardiac function in chronic heart failure","volume":"18","author":"Sundararaman","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.repc.2019.05.008_bib0965","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0970","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0975","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 inhibitors in heart failure: Diabetes and beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"10.1016\/j.repc.2019.05.008_bib0980","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199103000-00015","article-title":"Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme","volume":"17","author":"Seymour","year":"1991","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.repc.2019.05.008_bib0985","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/jm00034a005","article-title":"New dual inhibitors of neutral endopeptidase and angiotensin\u2010converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension","volume":"37","author":"Fourni\u00e9-Zaluski","year":"1994","journal-title":"J Med Chem."},{"key":"10.1016\/j.repc.2019.05.008_bib0990","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2019.05.008_bib0995","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib1000","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.repc.2019.05.008_bib1005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jcpt.12363","article-title":"Neprilysin inhibition with sacubitril\/valsartan in the treatment of heart failure: Mortality bang for your buck","volume":"41","author":"Ansara","year":"2016","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.repc.2019.05.008_bib1010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2019.05.008_bib1015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"13","author":"Packer","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.05.008_bib1020","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double\u2010blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255119304810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255119304810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:40Z","timestamp":1760108920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255119304810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0870255119304810"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2019.05.008","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A evolu\u00e7\u00e3o hist\u00f3rica do envolvimento dos sistemas neuro\u2010humorais no conhecimento da fisiopatologia e do tratamento da insufici\u00eancia card\u00edaca","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}